Personalized Perioperative Analgesia Platform (PPAP) for Cesarean Section

This study is developing a personalized approach to pain management for women having Caesarean sections, with the goal of reducing the risks of opioid medications for both mothers and their breastfed babies. Researchers are using genetic testing to understand how each woman's body processes opioids so that pain medications can be dosed more precisely and safely. Adult women scheduled for an elective C-section who are willing to receive in-hospital opioids are eligible, unless they have uncontrolled diabetes, pre-eclampsia, a history of opioid misuse, or significant kidney or liver disease. Participation involves genetic testing, receiving personalized opioid dosing, and providing information about pain control and any side effects in you and your baby. This summary was prepared to help patients understand the study in plain language.